Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Cancer Treatment Development appeared first on Investor's Business Daily.

Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Cancer Treatment Development

CAMBRIDGE, Mass., May  12, 2020  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting three oral presentations and two poster presentations at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually from May 12-15, 2020. Intellia researchers are presenting new data in support of NTLA-5001, the company’s engineered cell therapy candidate for the treatment of acute myeloid leukemia (AML). Intellia is also providing an update on NTLA-2002, its newest development candidate for the treatment of hereditary angioedema (HAE).

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2020 Results - Earnings Call Transcript

Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Shares of Intellia Therapeutics (NASDAQ:NTLA) were flat in pre-market trading after the company reported Q1 results.

Recap: Intellia Therapeutics Q1 Earnings

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings?

CAMBRIDGE, Mass., April  30, 2020  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins Intellia to lead its clinical development and regulatory organizations.

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer

CAMBRIDGE, Mass., March  31, 2020  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD).

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

CRISPR Therapeutics

Editas Medicine

The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.

The Top 3 Gene-Editing Stocks to Own in 2020

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q4 2019 Results - Earnings Call Transcript

Which of these two small-cap gene-editing stocks is a better investment?

Better Buy:  Editas Medicine vs.  Intellia

These two gene-editing stocks have a lot going for them. Let's consider pipelines, partnerships, and profits to make our choice.

Better Buy:  CRISPR Therapeutics vs.  Intellia

Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.

Intellia (NTLA) to Report Q4 Earnings: What's in Store?

Investors need to pay close attention to Intellia (NTLA) stock based on the movements in the options market lately.

Implied Volatility Surging for Intellia (NTLA) Stock Options

What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.

Here's Why CRISPR Stocks Fell in January

CAMBRIDGE, Mass., Jan.  09, 2020  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today provided an update on recent progress and the Company’s 2020 priorities and expected milestones.

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

Intellia Therapeutics: A Look Back At 2019 And Forward To 2020

Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.

Gene-Editing Stocks Dive As Creator Of CRISPR Babies Goes To Prison

Is  (NTLA) Outperforming Other Medical Stocks This Year?

Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year?

MeiraGTx Holdings plc

Pieris Pharma

uniQure

Vertex Pharmaceuticals

Global X Genomics & Biotechnology ETF

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Gene Therapy the Next Best Thing: Here's Why (Revised)

Gene Therapy the Next Best Thing: Here's Why

Novartis

There’s still a long way to go, but the newcomer is off to a good start.

CRISPR vs. Gene Therapy Round 1: What Investors Need to Know

Which stock wins in a matchup between these two gene-editing pioneers?

Better Buy: CRISPR Therapeutics vs. Intellia Therapeutics

As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NTLA).

Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue?

Intellia Therapeutics, Inc.'s (NTLA) CEO John Leonard on Q3 2019 Results - Earnings Call Transcript

News for Intellia Therapeutics Stock (NTLA)